Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101
NCT07168226
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
135
Enrollment
INDUSTRY
Sponsor class
Conditions
Cachexia; Cancer
Interventions
DRUG:
Active Comparator
DRUG:
ASCA101 24.32mg/kg
DRUG:
ASCA101 32.43mg/kg
DRUG:
Placebo
Sponsor
MetaFines